Advertisement
Advertisement
U.S. markets open in 8 minutes
Advertisement
Advertisement
Advertisement
Advertisement

AgeX Therapeutics, Inc. (AGE)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.6700-0.0100 (-1.47%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close0.6800
Open0.6800
Bid0.6200 x 3200
Ask0.0000 x 900
Day's Range0.6700 - 0.6980
52 Week Range0.5160 - 1.3900
Volume3,221
Avg. Volume27,885
Market Cap25.423M
Beta (5Y Monthly)1.52
PE Ratio (TTM)N/A
EPS (TTM)-0.2450
Earnings DateNov 14, 2022 - Nov 18, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for AGE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • AgeX Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 08/18/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • Business Wire

    AgeX Therapeutics Reports Second Quarter 2022 Financial Results

    ALAMEDA, Calif., August 12, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended June 30, 2022.

  • Business Wire

    Dr. Joanne Hackett Appointed Chairperson of AgeX Board of Directors

    ALAMEDA, Calif., May 18, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that Dr. Joanne Hackett has been appointed Chairperson of AgeX’s Board of Directors. Dr. Hackett joined the Board of Directors in December 2021. She will serve in a non-executive capacity as AgeX’s Chairperson. Dr. Greg Bailey, who served as AgeX’s Chairperson since 2018, will continue to serve as a member of AgeX’s

  • Business Wire

    AgeX Therapeutics Reports First Quarter 2022 Financial Results

    ALAMEDA, Calif., May 13, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended March 31, 2022.

Advertisement
Advertisement